← Back to Screener
Standard BioTools Inc. Common Stock (LAB)
Price$0.92
Favorite Metrics
Price vs S&P 500 (26W)-29.93%
Price vs S&P 500 (4W)-4.53%
Market Capitalization$381.29M
All Metrics
Book Value / Share (Quarterly)$1.10
P/TBV (Annual)1.47x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-4.48%
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-26.28%
Gross Margin (TTM)48.38%
Net Profit Margin (TTM)-70.72%
EPS (TTM)$-0.20
10-Day Avg Trading Volume3.58M
EPS Excl Extra (TTM)$-0.20
Revenue Growth (5Y)-9.18%
EPS (Annual)$-0.20
ROI (Annual)-29.41%
Gross Margin (Annual)49.86%
Net Profit Margin (5Y Avg)-95.42%
Cash / Share (Quarterly)$0.49
Revenue Growth QoQ (YoY)-49.07%
ROA (Last FY)-22.69%
Revenue Growth TTM (YoY)-39.29%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-51.72%
Operating Margin (TTM)-109.77%
Cash Flow / Share (Annual)$-0.40
P/B Ratio0.90x
P/B Ratio (Quarterly)1.16x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.49x
Net Interest Coverage (TTM)-15.25x
ROA (TTM)-13.35%
EPS Incl Extra (Annual)$-0.20
Current Ratio (Annual)5.70x
Quick Ratio (Quarterly)3.96x
3-Month Avg Trading Volume1.99M
52-Week Price Return-15.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.13
P/S Ratio (Annual)4.47x
Asset Turnover (Annual)0.28x
52-Week High$1.72
Operating Margin (5Y Avg)-86.05%
EPS Excl Extra (Annual)$-0.20
CapEx CAGR (5Y)-8.18%
26-Week Price Return-25.95%
Quick Ratio (Annual)4.94x
13-Week Price Return-35.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.19x
Enterprise Value$263.381
Revenue / Share Growth (5Y)-34.94%
Asset Turnover (TTM)0.19x
Book Value / Share Growth (5Y)29.38%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.49x
Pretax Margin (Annual)-113.33%
Cash / Share (Annual)$0.78
3-Month Return Std Dev50.63%
Gross Margin (5Y Avg)42.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-29.42%
Net Interest Coverage (Annual)-15.25x
EPS Basic Excl Extra (Annual)$-0.20
Receivables Turnover (TTM)4.52x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.20
Receivables Turnover (Annual)5.75x
ROI (TTM)-17.58%
P/S Ratio (TTM)3.60x
Pretax Margin (5Y Avg)-96.15%
Revenue / Share (Annual)$0.22
Tangible BV / Share (Annual)$1.17
Price vs S&P 500 (52W)-44.83%
Year-to-Date Return-23.63%
5-Day Price Return7.29%
EPS Normalized (Annual)$-0.20
ROA (5Y Avg)-26.47%
Net Profit Margin (Annual)-87.77%
Month-to-Date Return6.33%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-0.25
Operating Margin (Annual)-129.20%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-38.00%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.20
P/TBV (Quarterly)0.96x
P/B Ratio (Annual)1.38x
Inventory Turnover (TTM)1.80x
Pretax Margin (TTM)-93.86%
Book Value / Share (Annual)$1.25
Price vs S&P 500 (13W)-35.95%
Beta1.44x
Revenue / Share (TTM)$0.28
ROE (TTM)-17.59%
52-Week Low$0.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.86
3.86
3.86
3.86
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
LABStandard BioTools Inc. Common Stock | 3.60x | -9.18% | 48.38% | -109.77% | $0.92 |
AAgilent Technologies Inc. | 4.74x | 5.41% | 52.60% | 20.40% | $118.25 |
WATWaters Corp | 10.04x | 6.00% | 59.28% | 25.36% | $319.04 |
MTDMettler-Toledo International | 6.50x | 5.47% | 59.37% | 26.05% | $1290.84 |
ILMNIllumina Inc | 4.62x | 6.04% | 66.61% | 18.44% | $132.72 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $89.53 |
BIOBio-Rad Laboratories, Inc.Class A | 3.06x | 0.29% | 52.01% | 1.59% | $291.09 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.06x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.75x | 11.57% | 47.13% | 1.40% | $306.06 |
BRKRBruker Corporation | 1.73x | 11.57% | 47.13% | 1.40% | $38.94 |
AVTRAvantor, Inc. | 0.86x | 0.49% | 32.65% | -3.83% | $8.26 |
About
Standard BioTools develops and manufactures advanced analytical instruments for biomedical research, primarily using mass cytometry and microfluidics technologies to accelerate drug discovery. The company operates two core segments—Proteomics and Genomics—with Proteomics representing the largest revenue contributor. Its solutions enable researchers to gain deeper insights into health and disease mechanisms, supporting faster therapeutic development. The company generates the majority of its revenue from the Americas.